Proteasome inhibitor-based therapy for antibody-mediated rejection (Q26830410)

Alin L. Girnita

series ordinal

3

1 reference

language of work or name

1 reference

June 2012

1 reference

1 reference

81

1 reference

issue

11

1 reference

page(s)

1067-74

1 reference

HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss

cites work

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.502

7 January 2021

Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.502

7 January 2021

Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.502

7 January 2021

Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.502

7 January 2021

Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.502

7 January 2021

The effect of desensitization protocols on human splenic B-cell populations in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.502

7 January 2021

Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.502

7 January 2021

The proteasome, a novel protease regulated by multiple mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.502

7 January 2021

The proteasome: structure, function, and role in the cell

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.502

7 January 2021

The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.502

7 January 2021

Proteasome and peptidase function in MHC-class-I-mediated antigen presentation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.502

7 January 2021

Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.502

7 January 2021

How the ubiquitin-proteasome system controls transcription

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.502

7 January 2021

Ubiquitin-mediated proteolysis of vertebrate G1- and S-phase regulators

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.502

7 January 2021

Role of the unfolded protein response in cell death

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.502

7 January 2021

Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.502

7 January 2021

Use of systemic proteasome inhibition as an immune-modulating agent in disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.502

7 January 2021

A proteasome inhibitor effectively prevents mouse heart allograft rejection

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.502

7 January 2021

The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.502

7 January 2021

Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.502

7 January 2021

Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.502

7 January 2021

Dipeptide boronic acid, a novel proteasome inhibitor, prevents islet-allograft rejection

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.502

7 January 2021

Immunoproteasome beta subunit 10 is increased in chronic antibody-mediated rejection

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.502

7 January 2021

Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.502

7 January 2021

Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.502

7 January 2021

Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.502

7 January 2021

Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.502

7 January 2021

Subclinical rejection in stable positive crossmatch kidney transplant patients: incidence and correlations

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.502

7 January 2021

Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.502

7 January 2021

Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.502

7 January 2021

Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.502

7 January 2021

The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.502

7 January 2021

Abrogation of anti-HLA antibodies via proteasome inhibition

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.502

7 January 2021

A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.502

7 January 2021

Approval summary for bortezomib for injection in the treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.502

7 January 2021

Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.502

7 January 2021

Acute humoral rejection in a lung recipient: reversion with bortezomib

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.502

7 January 2021

Regulatory approval for new antihumoral therapies: addressing the barriers

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.502

7 January 2021

Dimensions Publication ID

Identifiers

DOI

10.1038/KI.2011.502

0 references

1000008890

0 references

PubMed publication ID

22336990

1 reference